Vazculep FDA Approval History
Last updated by Judith Stewart, BPharm on March 2, 2021.
Vazculep (phenylephrine hydrochloride) injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of hypotension resulting primarily from vasodilation in the setting of anesthesia.
Development Timeline for Vazculep
|Jun 30, 2014||Approval Flamel Technologies Announces FDA Approval of Vazculep|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.